MediWound (MDWD) Income from Discontinued Operations (2013 - 2014)

MediWound's (MDWD) quarterly Income from Discontinued Operations came in at 14000.0 in Q2 2014, up 101.29% year-on-year from 6955.05 in Q2 2013, and up 101.29% quarter-over-quarter from 1083000.0 in Q2 2013.

MediWound (MDWD) Income from Discontinued Operations (2013 - 2014) Analysis & Trends

MediWound's Income from Discontinued Operations history runs 2 years deep, the most recent figure standing at 14000.0 for Q2 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 MediWound 165.19 Mn 160.39 Mn 278,000.00 -

Historic Data

Download Data
DateValue
Jun 30, 2014 14,000.00
Jun 30, 2013 -1.08 Mn